Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

About Achillion Pharmaceuticals

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACHN
  • CUSIP: 00448Q20
Key Metrics:
  • Previous Close: $8.44
  • 50 Day Moving Average: $8.48
  • 200 Day Moving Average: $8.41
  • 52-Week Range: $5.57 - $10.95
  • Trailing P/E Ratio: 177.35
  • Foreward P/E Ratio: -27.16
  • P/E Growth: -0.81
  • Market Cap: $1.19B
  • Outstanding Shares: 136,680,000
  • Beta: 2.21
Profitability:
  • Return on Equity: -0.53%
  • Return on Assets: -0.50%
Debt:
  • Current Ratio: 33.44%
  • Quick Ratio: 33.45%
Additional Links:
Companies Related to Achillion Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $10.89 (25.30% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016Chardan CapitalBoost Price TargetSell$4.00 -> $5.00View Rating Details
9/22/2016WedbushInitiated CoverageOutperform$13.00View Rating Details
9/15/2016FBR & CoInitiated CoverageOutperform$16.00View Rating Details
8/9/2016Jefferies GroupReiterated RatingHoldView Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00View Rating Details
6/12/2016Leerink SwannReiterated RatingHoldView Rating Details
6/6/2016Robert W. BairdReiterated RatingOutperform$10.00View Rating Details
2/25/2016Maxim GroupReiterated RatingBuy$11.00 -> $8.00View Rating Details
12/8/2015William BlairReiterated RatingOutperform$16.00View Rating Details
5/23/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
4/6/2015Deutsche Bank AGReiterated RatingBuy$25.00 -> $20.00View Rating Details
3/4/2015Barclays PLCInitiated CoverageUnderweight$8.00View Rating Details
12/12/2014Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.18)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.16)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
Current Year EPS Consensus Estimate: $-0.63 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20163($0.16)($0.16)($0.16)
Q3 20162($0.19)($0.15)($0.17)
Q4 20165($0.23)($0.15)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Insider Ownership Percentage: 6.52%
Institutional Ownership Percentage: 79.43%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateHeadline
finance.yahoo.com logoAchillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating … (NASDAQ:ACHN)
finance.yahoo.com - September 24 at 3:17 PM
streetinsider.com logoAchillion Pharma (ACHN) Announces Positive SVR12 Data for Odalasvir, AL-335, and Simeprevir Phase 3 in Genotype 1 HCV (NASDAQ:ACHN)
www.streetinsider.com - September 24 at 3:17 PM
smarteranalyst.com logoCompany Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Announces ... (NASDAQ:ACHN)
www.smarteranalyst.com - September 24 at 3:17 PM
News IconBiotech news that matter for investors: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Vitae Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:ACHN)
voiceregistrar.com - September 23 at 3:31 PM
schaeffersresearch.com logoAnalyst Update: Enphase Energy Inc, Achillion Pharmaceuticals, Inc., and Netflix, Inc. - Schaeffers Research (blog) (NASDAQ:ACHN)
www.schaeffersresearch.com - September 23 at 3:31 PM
streetinsider.com logoAchillion Pharma (ACHN) Announces Positive SVR12 Data for Odalasvir, AL-335, and Simeprevir Phase 3 in Genotype ... - StreetInsider.com (NASDAQ:ACHN)
www.streetinsider.com - September 23 at 3:31 PM
finance.yahoo.com logoAchillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV (NASDAQ:ACHN)
finance.yahoo.com - September 23 at 3:31 PM
finance.yahoo.com logo11:51 am Achillion Pharma's Odalasvir shows potential to shorten the treatment duration to as little as six weeks in study results; No clinically significant laboratory, echocardiography, or ECG abnormalities were reported (shares halted) (NASDAQ:ACHN)
finance.yahoo.com - September 23 at 3:31 PM
publicnow.com logoAchillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV (NASDAQ:ACHN)
www.publicnow.com - September 23 at 3:31 PM
News IconAchillion Pharmaceuticals Inc. (NASDAQ:ACHN) Receives Consensus... (NASDAQ:ACHN)
www.bioportfolio.com - September 22 at 8:22 AM
News IconScorching Hot Biotech Stocks Tape: Juno Therapeutics Inc. (JUNO), Achillion Pharmaceuticals, Inc. (ACHN) - The Independent Republic (NASDAQ:ACHN)
theindependentrepublic.com - September 21 at 10:51 AM
News IconAchillion Pharmaceuticals, Inc.'s (ACHN): Stock Analysis Review - Hot Stocks Point (NASDAQ:ACHN)
www.hotstockspoint.com - September 21 at 10:51 AM
News IconAnalysts Predicting Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Stock Will Reach $4-17 Near Term - Frisco Fastball (NASDAQ:ACHN)
friscofastball.com - September 20 at 3:17 PM
News IconBiotech Stocks Worth a Closer Look: Achillion Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:ACHN)
voiceregistrar.com - September 20 at 3:17 PM
News IconQuarterly Sales Analysis of Achillion Pharmaceuticals, Inc ... - Newburgh Press (NASDAQ:ACHN)
newburghpress.com - September 20 at 3:17 PM
News IconTwo Biotechnology Names Are Hot: Keryx Biopharmaceuticals Inc. (KERX), Achillion Pharmaceuticals, Inc. (ACHN) - The Independent Republic (NASDAQ:ACHN)
theindependentrepublic.com - September 19 at 8:03 AM
News IconAchillion Pharmaceuticals Inc. (ACHN) to Post Q3 2016 Earnings of... (NASDAQ:ACHN)
www.bioportfolio.com - September 18 at 3:16 PM
News IconMean Consensus Price Target for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is Set at 10.111 - Frisco Fastball (NASDAQ:ACHN)
friscofastball.com - September 17 at 3:17 PM
thecountrycaller.com logoAchillion Pharmaceuticals Inc Has Over 107% Upside Potential (NASDAQ:ACHN)
www.thecountrycaller.com - September 17 at 8:05 AM
News IconFinancial Review of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Newburg Press (NASDAQ:ACHN)
newburghpress.com - September 16 at 11:57 AM
News IconHC Stocks Outlines! Achillion Pharmaceuticals, Inc. (ACHN), AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) - share market updates (press release) (NASDAQ:ACHN)
sharemarketupdates.com - September 16 at 11:57 AM
News IconAnalysts Valuations For Two Stocks: Triangle Petroleum Corporation (TPLM), Achillion Pharmaceuticals, Inc. (ACHN) - The Voice Registrar (NASDAQ:ACHN)
voiceregistrar.com - September 16 at 11:57 AM
News IconShares Gapping Up Before the Open: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Post News (NASDAQ:ACHN)
www.kentuckypostnews.com - September 15 at 12:09 PM
finance.yahoo.com logoCoverage initiated on Achillion Pharma by FBR & Co. (NASDAQ:ACHN)
finance.yahoo.com - September 15 at 12:09 PM
News IconStocks Cheering Investors with Mouthwatering Facts: Novo Nordisk (NYSE:NVO), Achillion Pharmaceuticals (NASDAQ ... - Street Wise Report (press release) (blog) (NASDAQ:ACHN)
streetwisereport.com - September 14 at 8:35 PM
News IconInvestor Scope: Checking in on Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Post News (NASDAQ:ACHN)
www.kentuckypostnews.com - September 13 at 3:17 PM
insidermonkey.com logoBiotech Movers: Lantheus Holdings Inc (LNTH) and Achillion Pharmaceuticals, Inc. (ACHN) - Insider Monkey (blog) (NASDAQ:ACHN)
www.insidermonkey.com - September 13 at 3:17 PM
News IconBiotech Movers: Lantheus Holdings Inc (LNTH) and Achillion Pharmaceuticals, Inc. (ACHN) (NASDAQ:ACHN)
feedproxy.google.com - September 13 at 7:48 AM
News IconWhat is the Street Saying About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)? - Frisco Fastball (NASDAQ:ACHN)
friscofastball.com - September 12 at 3:18 PM
News IconHC Stocks News= Synergy Pharmaceuticals Inc (SGYP), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - share market updates (press release) (NASDAQ:ACHN)
sharemarketupdates.com - September 12 at 8:04 AM
News IconHoning in on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Shares, Analysts Take Stock - Frisco Fastball (NASDAQ:ACHN)
friscofastball.com - September 11 at 3:15 PM
News IconShares Lower Over the Past Quarter: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Post News (NASDAQ:ACHN)
www.kentuckypostnews.com - September 11 at 8:04 AM
News IconRtw Investments Lowers stake in Achillion Pharmaceuticals (ACHN) - National Daily Press (NASDAQ:ACHN)
www.nationaldailypress.com - September 9 at 3:17 PM
streetinsider.com logoAchillion Pharma (ACHN) Announces Presentation of ODV + AL-335 ... - StreetInsider.com (NASDAQ:ACHN)
www.streetinsider.com - September 9 at 3:17 PM
News IconIntraday Active Biotech Stocks News: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), CoLucid Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:ACHN)
voiceregistrar.com - September 9 at 3:17 PM
investingnews.com logoAchillion Announces Results of Janssen’s Phase 2a Trial (NASDAQ:ACHN)
investingnews.com - September 9 at 8:05 AM
streetinsider.com logoAchillion Pharma (ACHN) Announces Presentation of ODV + AL-335 Phase 2a Data (NASDAQ:ACHN)
www.streetinsider.com - September 9 at 8:05 AM
nasdaq.com logoAchillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of (NASDAQ:ACHN)
www.nasdaq.com - September 9 at 8:05 AM
publicnow.com logoAchillion Announces 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV (NASDAQ:ACHN)
www.publicnow.com - September 9 at 8:05 AM
smarteranalyst.com logoCompany Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Presents Novel Research on Factor D Inhibition at ... - Smarter Analyst (NASDAQ:ACHN)
www.smarteranalyst.com - September 8 at 3:17 PM
benzinga.com logoWatch These 7 Huge Call Purchases In Wednesday Trade - Benzinga (NASDAQ:ACHN)
www.benzinga.com - September 7 at 3:17 PM
News IconAnalysts Valuations For Two Stocks: Groupon Inc (NASDAQ:GRPN ... - The Voice Registrar (NASDAQ:ACHN)
voiceregistrar.com - September 7 at 3:17 PM
News IconNotable Tuesday Option Activity: ACHN, WEX, VMW (NASDAQ:ACHN)
www.stockoptionschannel.com - September 6 at 8:26 PM
smarteranalyst.com logoCompany Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Presents Novel ... (NASDAQ:ACHN)
www.smarteranalyst.com - September 6 at 8:26 PM
streetinsider.com logoAchillion Pharma (ACHN) Announces Presentation of ACH-4471 ... - StreetInsider.com (NASDAQ:ACHN)
www.streetinsider.com - September 6 at 8:04 AM
News IconActive biotech company shares in the news: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Alexion ... - The Voice Registrar (NASDAQ:ACHN)
voiceregistrar.com - September 1 at 3:17 PM
publicnow.com logoAchillion to Present at Two Upcoming Investor Conferences (NASDAQ:ACHN)
www.publicnow.com - September 1 at 11:44 AM
capitalcube.com logoETF’s with exposure to Achillion Pharmaceuticals, Inc. : August 30, 2016 (NASDAQ:ACHN)
www.capitalcube.com - August 30 at 12:07 PM
News IconAnalyst Viewpoints on Price Reaction History: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Post Registrar (NASDAQ:ACHN)
postregistrar.com - August 29 at 3:35 PM
capitalcube.com logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : August 29, 2016 (NASDAQ:ACHN)
www.capitalcube.com - August 29 at 3:35 PM

Social

Achillion Pharmaceuticals (NASDAQ:ACHN) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff